Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PureTech Health plc - American Depositary Shares (NQ:PRTC)

17.42 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 17.42
Bid (Size) 16.40 (200)
Ask (Size) 18.01 (100)
Prev. Close 17.42
Today's Range 17.42 - 17.42
52wk Range 14.50 - 19.92
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
PureTech Health H1 Earnings Call Highlights ↗
PureTech Health (NASDAQ:PRTC) outlined progress across its portfolio in its 2026 half-year results call, highlighting external financings for Celea Therapeutics and Seaport Therapeutics, regulatory... 
Via MarketBeat
Topics Earnings Initial Public Offering
News headline image
PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference
From PureTech Health plc
Via Business Wire

Performance

52-Week Range 12.6% below 52-week high
17.42
14.5052W Low 19.9252W High

PureTech Health plc - American Depositary Shares (PRTC) traded between $14.50 and $19.92 over the past 52 weeks and last traded at $17.42, 12.6% below its 52-week high.

Past 12 Months
N/A
N/A
N/A
+12.4%
+3.7%
-8.2%
1W  
1M  
3M  
6M +$1.92
YTD +$0.63
1Y -$1.56

PRTC was -8.2% over the past year, +12.4% over six months, +3.7% year to date.

12 Months vs Market
PRTC
-8.2%
DIA
+9.5%
SPY
+14.6%
QQQ
+23.3%
IWM
+14.1%

Over the past 12 months PRTC returned -8.2% versus DIA (Dow) +9.5%, SPY (S&P 500) +14.6%, QQQ (Nasdaq 100) +23.3% and IWM (Russell 2000) +14.1%.

Volume & Liquidity
6M
12.6K
YTD
7.2K
1Y
5.6K

More News

Read More
News headline image
PureTech Announces Annual Results for Year Ended December 31, 2025
From PureTech Health plc
Via Business Wire
News headline image
PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange
From PureTech Health plc
Via Business Wire
News headline image
PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
From PureTech Health plc
Via Business Wire
News headline image
PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)
From PureTech Health plc
Via Business Wire
News headline image
PureTech (PRTC) Q1 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
PureTech Health: Notice of Results
From PureTech Health plc
Via Business Wire
News headline image
PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine
From PureTech Health plc
Via Business Wire
News headline image
PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers
From PureTech Health plc
Via Business Wire
News headline image
PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans
From PureTech Health plc
Via Business Wire
News headline image
PureTech to Present at the Leerink Partners Global Healthcare Conference
From PureTech Health plc
Via Business Wire
News headline image
PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
From PureTech Health plc
Via Business Wire
News headline image
PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference
From PureTech Health plc
Via Business Wire
News headline image
PureTech Appoints Robert Lyne as Chief Executive Officer
From PureTech Health plc
Via Business Wire
News headline image
PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
From PureTech Health plc
Via Business Wire
News headline image
PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
From PureTech Health plc
Via Business Wire
News headline image
PureTech’s Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting
From PureTech Health plc
Via Business Wire
News headline image
PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group
From PureTech Health plc
Via Business Wire
News headline image
PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF
From PureTech Health plc
Via Business Wire
News headline image
CoreWeave, Barrick Mining, FedEx And Other Big Stocks Moving Higher On Friday ↗
Via Benzinga
News headline image
PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy Volunteers
From PureTech Health plc
Via Business Wire
News headline image
PureTech (PRTC) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
PureTech Health Cash Runway Extended ↗
Via The Motley Fool
News headline image
Earnings Scheduled For August 28, 2025 ↗
Via Benzinga

Frequently Asked Questions

Is PureTech Health plc - American Depositary Shares publicly traded?
Yes, PureTech Health plc - American Depositary Shares is publicly traded.
What exchange does PureTech Health plc - American Depositary Shares trade on?
PureTech Health plc - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for PureTech Health plc - American Depositary Shares?
The ticker symbol for PureTech Health plc - American Depositary Shares is PRTC on the Nasdaq Stock Market
What is the current price of PureTech Health plc - American Depositary Shares?
The current price of PureTech Health plc - American Depositary Shares is 17.42
When was PureTech Health plc - American Depositary Shares last traded?
The last trade of PureTech Health plc - American Depositary Shares was at 05/20/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.